Investigative Ophthalmology & Visual Science · 2017 · 18 citations · 23 references
MedicineDermatologyOphthalmologyCell SignalingOcular PathologySignal TransductionEyelid InflammationEyelid PathologyImmunopathology Of The EyeOcular InflammationProtein Kinase CascadesErk SignalingExtracellular Signal-regulated Kinase PathwayIntracellular Signaling PathwaysMitogen-activated Protein Kinase PathwaysMitogen-activated Protein Kinase SignalingOcular RosaceaP38 Mitogen-activated Protein Kinase SignalingStress-activated Protein Kinases
Purpose: Rosacea-related cutaneous inflammation is a common cause of ocular surface disease. Currently, there are no specific pharmacologic therapies to treat ocular rosacea. Here, we aimed at determining the differences in intracellular signaling activity in eyelid skin from patients with and without ocular rosacea. Methods: This was an observational, comparative case series including 21 patients undergoing lower lid ectropion surgery at one practice during 2013 and 2014 (18 patients with rosacea, 13 control patients), and 24 paraffin-embedded archival samples from Albany Medical Center, selected randomly (12 patients with rosacea, 12 control patients). Cutaneous biopsies resulting from elective lower lid ectropion surgery were analyzed by Proteome Profiler Human Phospho-Kinase Array, Western blot, and/or immunohistochemistry. Results: Samples derived from ocular rosacea patients showed increased levels of phosphorylated (active) p38 and Erk kinases. Phosphoproteins were mainly localized to the epidermis of affected eyelids. Conclusions: This finding provides a novel potential therapeutic target for treatment of ocular rosacea and possibly other forms of rosacea. Further testing is required to determine if p38 and Erk activation have a causal role in ocular rosacea. The selective activation of keratinocytes in the affected skin suggests that topical pathway inhibition may be an effective treatment that will ultimately prevent ocular surface damage due to ocular rosacea.
23
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Jonathan K. Wilkin, Mark V. Dahl, Michael Detmar et al. · Journal of the American Academy of Dermatology · 2004 · 428 citations
The Contribution of Meibomian Disease to Dry Eye
Anthony J. Bron, John M. Tiffany · The Ocular Surface · 2004 · 337 citations